Almirall: RBC initiates coverage as a buyer
(CercleFinance.com) - On Tuesday Royal Bank of Canada initiated its coverage of the Almirall stock with an "outperform" rating and a target price of 13.
5 euros.
In a report yesterday evening, RBC said that it expects the Spanish pharmaceutical company's portfolio of dermatological products to generate "exceptional" growth in the coming years.
Over the past decade, Almirall has been strategically refocusing on dermatology, a high-growth specialty, analysts said.
After some setbacks, the group finally seems ready to achieve its targets thanks to its two flagship products, Ilumetri and lebrikizumab, they add.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5 euros.
In a report yesterday evening, RBC said that it expects the Spanish pharmaceutical company's portfolio of dermatological products to generate "exceptional" growth in the coming years.
Over the past decade, Almirall has been strategically refocusing on dermatology, a high-growth specialty, analysts said.
After some setbacks, the group finally seems ready to achieve its targets thanks to its two flagship products, Ilumetri and lebrikizumab, they add.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.